Aspirin vs vitamin K antagonist (VKA)
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes onlyRR 3 [0.12, 73.24]1 study · 440 participantsVery low